Table 1.
Baseline characteristics of 109 advanced non-small cell lung cancer patients.
| Characteristics | Subsets | No. | % |
|---|---|---|---|
| Gender | Male | 88 | 80.7% |
| Female | 21 | 19.3% | |
| Age (years) | Median | 65 | |
| Range | 36–85 | ||
| ECOG PS score | 0–1 | 92 | 84.4% |
| 2 | 17 | 15.6% | |
| Smoking status | Current/former | 63 | 57.8% |
| Never | 46 | 42.2% | |
| Histology | Adenocarcinoma | 60 | 55.0% |
| Squamous carcinoma | 46 | 42.2% | |
| Large cell carcinoma | 3 | 2.8% | |
| Stage | Ⅳ | 102 | 93.6% |
| ⅢB | 7 | 6.4% | |
| PD-L1 states test | ≥50% | 23 | 21.1% |
| 1–49% | 33 | 30.3% | |
| <1% | 17 | 15.6% | |
| Unknown | 36 | 33.0% | |
| Driver gene alteration | EGFR/ALK/ROS1 positive | 9 | 8.3% |
| Negative/unknown | 100 | 91.7% | |
| Treatment line | First | 41 | 37.6% |
| Second | 39 | 35.8% | |
| Third | 15 | 13.8% | |
| Fourth or later line | 14 | 12.8% | |
| Combination treatment | Yes | 63 | 57.8% |
| No | 46 | 42.2% |
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death ligand 1; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, V-ros UR2 sarcoma virus oncogene homolog 1.